Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 6/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504030 | 0.86 | MAP2 (0.55) | MAP2PTGS2MEN1KMT2AATM | |
| SCHEMBL4575493 | 0.84 | PTGS2 (0.47) | MAP2PTGS2ALOX15MEN1KMT2A | |
| SCHEMBL22450909 | 0.79 | MAP2 (0.52) | MAP2PTGS2ALOX15MEN1KMT2A | |
| SCHEMBL16610191 | 0.77 | ALOX15 (0.81) | ALOX15 | |
| SCHEMBL1504139 | 0.77 | ALOX15 (0.61) | ALOX15MEN1KMT2AMAPT | |
| SCHEMBL8689806 | 0.74 | MAP2 (0.62) | MAP2PTGS2MEN1KMT2AMAPT | |
| SCHEMBL3037898 | 0.72 | MAP2 (0.63) | MAP2PTGS2MEN1KMT2AMAPT | |
| SCHEMBL23498272 | 0.72 | CSF1R (0.49) | MAP2 | |
| SCHEMBL27442503 | 0.72 | MAP2 (0.59) | MAP2 | |
| SCHEMBL30044896 | 0.72 | CSF1R (0.49) | MAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161561-A1 | Novel Processing for the Preparation of a Benzofuran | ARPIDA (CH) | 2008-07-03 | — | — | US | claimed |
| US-20080161561-A1 | Novel Processing for the Preparation of a Benzofuran | ARPIDA (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161561-A1 | Novel Processing for the Preparation of a Benzofuran | ARPIDA (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161561-A1 | Novel Processing for the Preparation of a Benzofuran | ARPIDA (CH) | 2008-07-03 | — | — | US | disclosed |
| EP-1856109-A1 | NOVELL PROCESSES FOR THE PREPARATION OF A BENZOFURAN | Arpida AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006087140-A1 | NOVELL PROCESSES FOR THE PREPARATION OF A BENZOFURAN | ARPIDA AG (CH) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161561-A1 | Novel Processing for the Preparation of a Benzofuran | DHFR, DHPS, DPYD | MAP2 3409/4885PTGS2 972/4885ALOX15 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.